July 17, 2023
Leadership of the UK Chinese Business Association (UKCBA), including chairman, Mr. Jinlong Zhang, and secretary-general and executive vice chairman, Mr. Jie Yin, along with the UK delegation, visited HighTide Therapeutics, Inc. (“HighTide”). They were accompanied by the president of the Korea Busan-Ulsan-Gyeongnam Chinese Chamber of Commerce and Industry (KBUGCCCI), Mr. Dafu Fan, and other business leaders. The HighTide management team warmly welcomed the dignitaries and conducted in-depth discussions together.
HighTide is the only company which the Chinese Chamber of Commerce visited during its trip to Shenzhen. Dr. Liping Liu, founder and CEO of HighTide, welcomed the distinguished guests who had travelled a great distance and expressed her heartfelt thanks. Afterwards, she introduced the company’s history, scientific research capability, and product pipeline. HighTide has independently developed the world's first multifunctional, multi-targeted new molecular entity, and applied for 128 patent authorizations and applications in major countries and regions around the world. Since inception, HighTide has conducted clinical trials in multiple countries such as the United States, Australia, Canada, and China. Moreover, HighTide has presented breakthrough development results at authoritative global liver disease conferences for several consecutive years and published in numerous world-renowned medical journals.
Mr. Jinlong Zhang and other entrepreneurs recognized HighTide's commitment to developing novel new drugs in the spirit of artemisinin. They also conducted in-depth discussions about the company's future development for its multi-targeted novel drugs.
In the future, both parties look forward to maintaining close contact, carrying out in-depth, multi-faceted cooperation, and jointly promoting prosperous development of the healthcare industry.
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class, multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.